These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 34740055)

  • 1. The Mpro structure-based modifications of ebselen derivatives for improved antiviral activity against SARS-CoV-2 virus.
    Qiao Z; Wei N; Jin L; Zhang H; Luo J; Zhang Y; Wang K
    Bioorg Chem; 2021 Dec; 117():105455. PubMed ID: 34740055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Se-S Bond Formation in the Covalent Inhibition Mechanism of SARS-CoV-2 Main Protease by Ebselen-like Inhibitors: A Computational Study.
    Parise A; Romeo I; Russo N; Marino T
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Biosafety Level 1 Cellular Assay for Identifying Small-Molecule Antivirals Targeting the Main Protease of SARS-CoV-2: Evaluation of Cellular Activity of GC376, Boceprevir, Carmofur, Ebselen, and Selenoneine.
    Fukumoto Y; Suzuki N; Hara R; Tanaka YK; Ogra Y
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ebsulfur and Ebselen as highly potent scaffolds for the development of potential SARS-CoV-2 antivirals.
    Sun LY; Chen C; Su J; Li JQ; Jiang Z; Gao H; Chigan JZ; Ding HH; Zhai L; Yang KW
    Bioorg Chem; 2021 Jul; 112():104889. PubMed ID: 33915460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Activity Studies Reveal Scope for Optimisation of Ebselen-Type Inhibition of SARS-CoV-2 Main Protease.
    Thun-Hohenstein STD; Suits TF; Malla TR; Tumber A; Brewitz L; Choudhry H; Salah E; Schofield CJ
    ChemMedChem; 2022 Feb; 17(4):e202100582. PubMed ID: 34850566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico Studies on the Interaction between Mpro and PLpro From SARS-CoV-2 and Ebselen, its Metabolites and Derivatives.
    Nogara PA; Omage FB; Bolzan GR; Delgado CP; Aschner M; Orian L; Teixeira Rocha JB
    Mol Inform; 2021 Aug; 40(8):e2100028. PubMed ID: 34018687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of potential inhibitors targeting SARS-CoV-2 Mpro.
    Zhou WW; Li DS; Chen Y; You BQ; Zheng YF; Li Y; Si SY; Zhang J
    Eur Rev Med Pharmacol Sci; 2024 Sep; 28(18):4313-4325. PubMed ID: 39359203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Machine learning-based QSAR and LB-PaCS-MD guided design of SARS-CoV-2 main protease inhibitors.
    Toopradab B; Xie W; Duan L; Hengphasatporn K; Harada R; Sinsulpsiri S; Shigeta Y; Shi L; Maitarad P; Rungrotmongkol T
    Bioorg Med Chem Lett; 2024 Sep; 110():129852. PubMed ID: 38925524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives.
    Amporndanai K; Meng X; Shang W; Jin Z; Rogers M; Zhao Y; Rao Z; Liu ZJ; Yang H; Zhang L; O'Neill PM; Samar Hasnain S
    Nat Commun; 2021 May; 12(1):3061. PubMed ID: 34031399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions.
    Shawky AM; Almalki FA; Alzahrani HA; Abdalla AN; Youssif BGM; Ibrahim NA; Gamal M; El-Sherief HAM; Abdel-Fattah MM; Hefny AA; Abdelazeem AH; Gouda AM
    Eur J Med Chem; 2024 Nov; 277():116704. PubMed ID: 39121741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigating the Inhibition of Diindolylmethane Derivatives on SARS-CoV-2 Main Protease.
    Li W; Chang X; Zhou H; Yu W; Wang R; Chang J
    J Mol Recognit; 2024 Nov; 37(6):e3101. PubMed ID: 39221493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants.
    Le UNP; Chang YJ; Lu CH; Chen Y; Su WC; Chao ST; Baltina LA; Petrova SF; Li SR; Hung MC; Lai MMC; Baltina LA; Lin CW
    Antiviral Res; 2024 Jul; 227():105920. PubMed ID: 38821317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
    Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
    Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface.
    Liang J; Karagiannis C; Pitsillou E; Darmawan KK; Ng K; Hung A; Karagiannis TC
    Comput Biol Chem; 2020 Dec; 89():107372. PubMed ID: 32911432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insight into crystal structures and identification of potential styrylthieno[2,3-
    El Bakri Y; Ahmad B; Saravanan K; Ahmad I; Bakhite EA; Younis O; Al-Waleedy SAH; Ibrahim OF; Nafady A; Mague JT; Mohamed SK
    J Biomol Struct Dyn; 2024 May; 42(8):4325-4343. PubMed ID: 37318002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deciphering inhibitory activity of marine algae Ecklonia cava phlorotannins against SARS CoV-2 main protease: A coupled in-silico docking and molecular dynamics simulation study.
    Chakraborty A; Ghosh R; Barik S; Mohapatra SS; Biswas A; Chowdhuri S
    Gene; 2024 Oct; 926():148620. PubMed ID: 38821329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural and Biochemical Analysis of the Dual Inhibition of MG-132 against SARS-CoV-2 Main Protease (Mpro/3CLpro) and Human Cathepsin-L.
    Costanzi E; Kuzikov M; Esposito F; Albani S; Demitri N; Giabbai B; Camasta M; Tramontano E; Rossetti G; Zaliani A; Storici P
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
    Ghosh A; Chakraborty M; Chandra A; Alam MP
    J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents.
    Zagórska A; Czopek A; Fryc M; Jończyk J
    Biomolecules; 2024 Jul; 14(7):. PubMed ID: 39062511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repurposing of antimycobacterium drugs for COVID-19 treatment by targeting SARS CoV-2 main protease: An in-silico perspective.
    Chakraborty A; Ghosh R; Soumya Mohapatra S; Barik S; Biswas A; Chowdhuri S
    Gene; 2024 Sep; 922():148553. PubMed ID: 38734190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.